Kinnate Biopharma Inc.

Kinnate Biopharma Inc.verified

KNTE

Price:

$2.65

Market Cap:

$124.99M

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinna...[Read more]

Industry

Biotechnology

IPO Date

2020-12-03

Stock Exchange

NASDAQ

Ticker

KNTE

The PE Ratio as of July 2024 (TTM) for Kinnate Biopharma Inc. (KNTE) is -0.95

According to Kinnate Biopharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.95. This represents a change of -31.33% compared to the average of -1.39 of the last 4 quarters.

Kinnate Biopharma Inc. (KNTE) Historical PE Ratio (quarterly & annually)

How has KNTE PE Ratio performed in the past?

The mean historical PE Ratio of Kinnate Biopharma Inc. over the last ten years is -42.97. The current -0.95 PE Ratio has changed 121.82% with respect to the historical average. Over the past ten years (40 quarters), KNTE's PE Ratio was at its highest in in the September 2023 quarter at -0.54. The PE Ratio was at its lowest in in the December 2019 quarter at -107.76.

Quarterly (TTM)
Annual

Average

-42.97

Median

-28.73

Minimum

-141.80

Maximum

-0.98

Kinnate Biopharma Inc. (KNTE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kinnate Biopharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 156.65%

Maximum Annual PE Ratio = -0.98

Minimum Annual Increase = -82.30%

Minimum Annual PE Ratio = -141.80

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.98-58.43%
2022-2.36-72.72%
2021-8.64-82.30%
2020-48.81-65.58%
2019-141.80156.65%

Kinnate Biopharma Inc. (KNTE) Average PE Ratio

How has KNTE PE Ratio performed in the past?

The current PE Ratio of Kinnate Biopharma Inc. (KNTE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.99

5-year avg

-40.52

10-year avg

-42.97

Kinnate Biopharma Inc. (KNTE) PE Ratio vs. Peers

How is KNTE’s PE Ratio compared to its peers?

Kinnate Biopharma Inc.’s PE Ratio is greater than Ambrx Biopharma Inc. (-25.13), greater than Acelyrin, Inc. (-2.65), less than Windtree Therapeutics, Inc. (-0.28), less than Palisade Bio, Inc. (-0.25), greater than Century Therapeutics, Inc. (-1.17), less than Passage Bio, Inc. (-0.60), less than Homology Medicines, Inc. (-0.01), greater than Generation Bio Co. (-1.13), greater than Stoke Therapeutics, Inc. (-5.79), greater than Gracell Biotechnologies Inc. (-12.58), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Monte Rosa Therapeutics, Inc. (-1.89), greater than Design Therapeutics, Inc. (-3.92), greater than Erasca, Inc. (-3.52), less than Kronos Bio, Inc. (-0.64), greater than C4 Therapeutics, Inc. (-3.27), greater than Edgewise Therapeutics, Inc. (-17.67), less than Surrozen, Inc. (-0.50), less than Bolt Biotherapeutics, Inc. (-0.44), greater than Larimar Therapeutics, Inc. (-11.07), greater than Keros Therapeutics, Inc. (-8.89), less than Kezar Life Sciences, Inc. (-0.45),

Build a custom stock screener for Kinnate Biopharma Inc. (KNTE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kinnate Biopharma Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kinnate Biopharma Inc. (KNTE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kinnate Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Kinnate Biopharma Inc.'s PE Ratio?

How is the PE Ratio calculated for Kinnate Biopharma Inc. (KNTE)?

What is the highest PE Ratio for Kinnate Biopharma Inc. (KNTE)?

What is the 3-year average PE Ratio for Kinnate Biopharma Inc. (KNTE)?

What is the 5-year average PE Ratio for Kinnate Biopharma Inc. (KNTE)?

How does the current PE Ratio for Kinnate Biopharma Inc. (KNTE) compare to its historical average?